Kristie Rosa

A combination of cabozantinib and atezolizumab improved the PFS in patients with Advanced HCC

Epoetin alfa-epbx (Retacrit), the biosimilar to epoetin alfa (Procrit/Epogen), has been launched in the United States at a significant discount. The shipment of the biosimilar to wholesalers throughout the United States began on Nov. 12, 2018.